IGC Pharma (IGC) Short term Debt (2011 - 2026)

IGC Pharma (IGC) has reported Short term Debt for 11 consecutive years, with $726000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $726000.0 in Q1 2026; TTM through Mar 2026 was $726000.0, a N/A change from a year earlier, with the FY2026 full-year figure at $726000.0, changed N/A from the prior year.
• Short term Debt was $726000.0 for Q1 2026 at IGC Pharma, up from $180000.0 in the prior quarter.
• Over five years, Short term Debt peaked at $726000.0 in Q1 2026 and troughed at $3000.0 in Q1 2022.
• A 3-year average of $228000.0 and a median of $91500.0 in 2022 frame the typical range for Short term Debt.
• The widest YoY moves for Short term Debt: up 0.0% in 2022, down 99.01% in 2022.
• Over 3 years, Short term Debt stood at $3000.0 in 2022, then jumped by 5900.0% to $180000.0 in 2025, then surged by 303.33% to $726000.0 in 2026.
• The last three Short term Debt figures came in at $726000.0 (Q1 2026), $180000.0 (Q4 2025), and $3000.0 (Q2 2022), per Business Quant data.